AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02101554
Drug: ages 12-17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
Trial: NCT00640146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
Trial: NCT01883297
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
Trial: NCT04127695
Drug: Placebo ABBV-0805
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ABBV-0805 administered by IV infusion.
Trial: NCT01708720
Drug: IPV
RxNorm normalized name: IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03393689
Drug: One injection of 68Ga-NODAGA-E[c(RGDyK)]2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
Trial: NCT04055467
Drug: [F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain imaging of alpha-7 nicotinic acetylcholine receptors
Trial: NCT01708720
Drug: Adjuvanted Sabin-IPV
RxNorm normalized name: Juniperus sabina leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00958971
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
Trial: NCT01975701
Drug: BGJ398
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral use.
Trial: NCT04005807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT01717391
Drug: fluorothymidine F 18
RxNorm normalized name: FLUOROTHYMIDINE F-18
DrugBank: Alovudine F-18 (DB14930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
Trial: NCT01301183
Drug: RhIGF-1 with transdermal 17-beta estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.~Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
Trial: NCT01301183
Drug: Placebo and transdermal 17-beta estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
Trial: NCT04161976
Drug: LY900027
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY900027 administered to participants with T1DM using CSII.
Trial: NCT01928888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
Trial: NCT03761849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal injection
Trial: NCT00198666
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Elemental Zinc
Trial: NCT01272388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
Trial: NCT00874172
Drug: Rapid optimized analgesic strategy
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus
Trial: NCT00874172
Drug: current analgesic strategy
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration
Trial: NCT02636972
Drug: OCPs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra
Trial: NCT02665624
Drug: Senna alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of bowel cleansing and patient comfort.
Trial: NCT01807234
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Trial: NCT01807234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one spray in each nostril and placebo one nasal spray.
Trial: NCT02967770
Drug: Standard of Care Second Line Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03886688
Drug: HEC53856
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT03886688
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT04088305
Drug: Individualized therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage of Vancomycin decided by a serum trough concentration model, instead of decided by attending physician
Trial: NCT00591084
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion placebo (group B)once a day and continued for 14 days
Trial: NCT03460470
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Sildenafil
Trial: NCT02771600
Drug: Topical anaesthetic cream
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT02050334
Drug: CC100
RxNorm normalized name: CENTRAL LINE DRESSING KIT M#BSIPICC1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC100 reconstituted in diluent
Trial: NCT02050334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluent. Amount to match CC100 dose.
Trial: NCT03075267
Drug: PT010 (BGF MDI) 320/14.4/9.6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
Trial: NCT03075267
Drug: PT010 (BGF MDI) 160/14.4/9.6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
Trial: NCT03075267
Drug: PT003 (GFF MDI) 14.4/9.6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
Trial: NCT02662023
Drug: Basal
RxNorm normalized name: Basaljel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.
Trial: NCT04282200
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous ketorolac 30 mg every 6 hours
Trial: NCT02497547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00556296
Drug: NRP104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRP104 30mg capsule once daily in a.m.
Trial: NCT00556296
Drug: NRP104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRP104 50mg capsule once daily in a.m.
Trial: NCT00556296
Drug: NRp104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRP104 70mg capsule once daily in a.m.
Trial: NCT00556296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04332991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
Trial: NCT01263223
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01263223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00000499
Drug: chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01129011
Drug: PN400 (VIMOVO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
Trial: NCT01129011
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg dosed twice daily (bid) orally
Trial: NCT00968097
Drug: 123-I MNI-340
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
Trial: NCT00291928
Drug: Part B
RxNorm normalized name: Hem-Care Premium 7-Part Blend Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
Trial: NCT03423537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100IU per day containing N/S 0.9% will be injected
Trial: NCT02073656
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT01525875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg (one 500 mg capsule two times daily) of placebo.
Trial: NCT05256758
Drug: Placental Lactogen
RxNorm normalized name: Human placental lactogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 patients randomised to receive placebo for 6 months.
Trial: NCT02831088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
Trial: NCT00237718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
Trial: NCT00237718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for alpha lipoic acid; 2 pills daily for 6 months
Trial: NCT01870687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02446912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV administration every 4 weeks from Week 0 to Week 48
Trial: NCT02270606
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02270606
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00942799
Drug: Genz-644282 (28-day dosing schedule)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
Trial: NCT00942799
Drug: Genz-644282 (21-day dosing schedule)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
Trial: NCT01133678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel(175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Placebo PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
Trial: NCT02720783
Drug: Placebo vaginal pessary
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04586335
Drug: CYH33
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor
Trial: NCT00394771
Drug: Seasonale®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
Trial: NCT00394771
Drug: Portia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
Trial: NCT00811993
Drug: RG1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
Trial: NCT00811993
Drug: RO1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27mg/kg iv, monotherapy
Trial: NCT00811993
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as prescribed
Trial: NCT00811993
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as prescribed
Trial: NCT00811993
Drug: pemetrexel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as prescribed
Trial: NCT05224388
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of heparin in either prophylactic dose regimen or therapeutic dose regimen
Trial: NCT02305797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT01803828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 20 mg/die (1 capsule)
Trial: NCT02720978
Drug: vaginal prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery.
Trial: NCT01614899
Drug: SM-13496 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily orally
Trial: NCT01614899
Drug: SM-13496 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily orally
Trial: NCT01614899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily orally
Trial: NCT04203368
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil.
Trial: NCT03343509
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet
Trial: NCT01156051
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
Trial: NCT03343509
Drug: Placebo Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Ointment
Trial: NCT00449033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
Trial: NCT01176409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
Trial: NCT00684632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00684632
Drug: KW-2246 (fentanyl citrate)
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: KW-2246 (fentanyl citrate)
Trial: NCT00050167
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500 mg/m\^2 by mouth Twice Daily x 2 Weeks
Trial: NCT03623776
Drug: JS001
RxNorm normalized name: Janus Kinase Inhibitor JS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
Trial: NCT04366648
Drug: JK-1201I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: malignant solid tumor that has been confirmed by histopathology and/or cytology
Trial: NCT02766764
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI
Trial: NCT02766764
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection
Trial: NCT04058158
Drug: SB12 (proposed eculizumab biosimilar)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
Trial: NCT02855892
Drug: GV1001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04143802
Drug: LY3437943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04143802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00358722
Drug: Fermagate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablet 500mg
Trial: NCT03508882
Drug: Saline Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).
Trial: NCT01798238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
Trial: NCT02577848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo were taken daily for 7 days
Trial: NCT03278808
Drug: Chloroquine-Azithromycin (CQ/AZ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
Trial: NCT01931683
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
Trial: NCT01052831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-100 mg qd for 8 weeks
Trial: NCT02172040
Drug: Matched placebo capsule for over-encapsulated celecoxib capsule
RxNorm normalized name: celecoxib Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks